Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Arvinas
Deal Size : Undisclosed
Deal Type : Partnership
Arvinas picks Certara for Its Targeted Protein Degradation Research
Details : Certara’s D360 platform enables Arvinas to accelerate lead identification and optimization processes for oncology, neurodegenerative diseases, and therapies for “undruggable” targets.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Arvinas
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Trifarotene
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Galderma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Certara's Simcyp population-based Simulator was used to support Galderma’s successful U.S. FDA new drug application for AKLIEF (trifarotene) Cream, 0.005% for the topical treatment of acne.
Product Name : Aklief
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 01, 2020
Lead Product(s) : Trifarotene
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Galderma
Deal Size : Undisclosed
Deal Type : Partnership